Inspire Medical Systems, Inc. (NYSE:INSP) is a company that specializes in innovative medical solutions, particularly focusing on sleep apnea treatments. The company is known for its Inspire therapy, a device that offers an alternative to traditional treatments like CPAP machines. As of December 8, 2025, Piper Sandler set a price target of $165 for INSP, suggesting a potential upside of 20.61% from its current trading price of $136.81.
Despite this optimistic price target, Inspire Medical is currently embroiled in a class action lawsuit led by the Schall Law Firm. The lawsuit claims that the company violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5. These allegations are serious, as they pertain to securities fraud, which can significantly impact investor confidence and stock performance.
The lawsuit targets investors who purchased INSP securities between August 6, 2024, and August 4, 2025. Shareholders who suffered losses during this period are urged to contact the Schall Law Firm by January 5, 2026, to explore their legal options. This legal challenge could potentially affect the stock's future performance and investor sentiment.
Currently, INSP's stock price is $136.81, reflecting a decrease of 2.30% or $3.22. The stock has fluctuated today, trading between $136.61 and $142.26. Over the past year, INSP has seen a high of $216.01 and a low of $70.77, indicating significant volatility. The company's market capitalization stands at approximately $4.05 billion, with a trading volume of 875,129 shares.
Inspire Medical's current legal issues and stock performance are crucial factors for investors to consider. While Piper Sandler's price target suggests potential growth, the ongoing lawsuit and recent stock fluctuations highlight the risks involved. Investors should closely monitor these developments to make informed decisions about their investments in INSP.
